JoshuaTolkienKantrowitzMD

Psychiatry • New York, NY

Associate Professor of Clinical Psychiatry at Columbia University

Join to view full profile

Dr. Kantrowitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kantrowitz's full profile

Already have an account?

Office
1051 Riverside Drive
New York State Psychiatric Institute
New York, NY 10032
Phone+1 646-774-6738

Education & Training

Yale-New Haven Medical CenterResidency, Psychiatry, 2003 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2003

Certifications & Licensure

NY State Medical License 2007 - 2026
CT State Medical License 2005 - 2007
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Conversion to Antipsychotic Monotherapy Start of enrollment: 2007 Dec 01
Terminated
Not Applicable
N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia Start of enrollment: 2012 Mar 01
Unknown status
Phase 2
NMDA Antagonists in Bipolar Depression Start of enrollment: 2013 Mar 01
Completed
Phase 4
D-serine and Cognitive Remediation in Schizophrenia Start of enrollment: 2014 Aug 01
Completed
Phase 2
Clinical Trial of AVL-3288 in Schizophrenia Patients Start of enrollment: 2016 Nov 01
Completed
Phase 1
Target Engagement of D-cycloserine (DCS)
CVN058 Effect on Mismatch Negativity in Schizophrenics Start of enrollment: 2018 Nov 09
Completed
Phase 1
D-serine Augmentation of Neuroplasticity Start of enrollment: 2019 Mar 13
Completed
Phase 1, Phase 2
Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects Start of enrollment: 2019 Oct 07
Completed
Join now to see all

Publications & Presentations

PubMed

Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.
Pejman Sehatpour, Joshua T Kantrowitz
Biological Psychiatry. 2025-01-15
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry.
Joshua T Kantrowitz, Daniel C Javitt
Advances in Neurobiology. 2024-01-01
1 citations
Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, p...
Viraj Govani, Adithya M Shastry, Dan V Iosifescu, Preetika Govil, Megan R Mayer
Schizophrenia Research. 2023-10-01

Journal Articles

A Multicenter Study of Ketamine Effects on Functional Connectivity: Large Scale Network Relationships, Hubs and Symptom Mechanisms
Ragy R Girgis, Richard J Maddock, John D Ragland, Daniel C Javitt, Cameron S Carter, Joshua T Kantrowitz, Jeffrey Lieberman, John H Krystal, Lawrence S Kegeles, Willia..., ScienceDirect

Press Mentions

Treatment of Tardive DyskinesiaAugust 13th, 2024
Karuna’s Experimental Schizophrenia Drug Succeeds in Advanced StudyAugust 8th, 2022
Some Caplyta Results in Schizophrenia Reach PrintJanuary 7th, 2020
Join now to see all